The urine albumin-to-creatinine ratio is a reliable indicator for evaluating complications of chronic kidney disease and progression in IgA nephropathy in China by Huan, Lu et al.
The urine albumin-to-creatinine ratio is a reliable
indicator for evaluating complications of chronic kidney
disease and progression in IgA nephropathy in China
Lu Huan,I Luo Yuezhong,II,* Wang Chao,II Tu HaiTaoII
IGuangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, PR, China. IIThe First Affiliated Hospital of Guangzhou University of
Traditional Chinese Medicine, Department of Nephrology, Guangzhou, Guangdong, PR, China.
OBJECTIVE: This study investigated the correlation between the albumin-to-creatinine ratio in the urine and
24-hour urine proteinuria and whether the ratio can predict chronic kidney disease progression even more
reliably than 24-hour proteinuria can, particularly in primary IgA nephropathy.
METHODS: A total of 182 patients with primary IgA nephropathy were evaluated. Their mean urine albumin-to-
creatinine ratio and 24-hour proteinuria were determined during hospitalization. Blood samples were
also analyzed. Follow-up data were recorded for 44 patients. A cross-sectional study was then conducted to test
the correlation between these parameters and their associations with chronic kidney disease complications.
Subsequently, a canonical correlation analysis was employed to assess the correlation between baseline
proteinuria and parameters of the Oxford classification. Finally, a prospective observational study was performed
to evaluate the association between proteinuria and clinical outcomes. Our study is registered in the Chinese
Clinical Trial Registry, and the registration number is ChiCTR-OCH-14005137.
RESULTS: A strong correlation (r=0.81, po0.001) was found between the ratio and 24-hour proteinuria except in
chronic kidney disease stage 5. First-morning urine albumin-to-creatinine ratios ofX125.15, 154.44 and 760.31 mg/g
reliably predicted equivalent 24-hour proteinuria ‘thresholds’ of X0.15, 0.3 and 1.0 g/24 h, respectively. In conti-
nuous analyses, the albumin-to-creatinine ratio was significantly associated with anemia, acidosis, hypoalbuminemia,
hyperphosphatemia, hyperkalemia, hypercholesterolemia and higher serum cystatin C. However, higher 24-hour
proteinuria was only associated with hypoalbuminemia and hypercholesterolemia. Higher tubular atrophy and
interstitial fibrosis scores were also associated with a greater albumin-to-creatinine ratio, as observed in the canonical
correlation analysis. Finally, the albumin-to-creatinine ratio and 24-hour proteinuria were associated with renal
outcomes in univariate analyses.
CONCLUSION: This study supports the recommendation of using the albumin-to-creatinine ratio, rather than
24-hour proteinuria, to monitor proteinuria and prognosis in primary IgA nephropathy.
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’ INTRODUCTION
IgA nephropathy (IgAN) is a relatively prevalent primary
chronic glomerular disease occurring worldwide (1) and is
the most frequently diagnosed primary glomerular disease in
China (2). Proteinuria, microscopic hematuria and hyperten-
sion, either alone or in combination, are the common clinical
presentations in adults (3,4). Although the clinical course
is generally gradual, progression to end-stage renal disease
(ESRD) is estimated to occur in 20-40% of IgAN patients
within 20 years (5-7). Thus, earlier diagnoses and better
monitoring of the clinical course or response to therapy are
significantly important for good outcomes.
An impaired glomerular filtration rate (GFR), sustained
hypertension and substantial proteinuria independently
predict a poor clinical course in IgAN (4,8). Due to the lack
of a disease-targeted treatment, control of proteinuria and
blood pressure is emphasized by both the KDIGO and
KDOQI guidelines. Therefore, it is very important that
physicians monitor the levels of proteinuria and blood
pressure to assess patients’ responses to therapy. Previous
studies have demonstrated that time-averaged urinary
protein excretion of more than 1.0 g per day indicates an
extremely elevated risk of ESRD in IgAN (2,7,9). However,
24-hour urine protein collection is time consuming and oftenDOI: 10.6061/clinics/2016(05)01
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imprecise (10). Albuminuria categorization constitutes one of
the chronic kidney disease (CKD) classification systems and
measuring the albumin-to-creatinine ratio (ACR) in the urine
has been recommended as a standard preferable to monitor-
ing proteinuria (11,12). Many studies that have evaluated the
correlation between spot urine protein levels or the ACR
and 24-hour urine proteinuria (UTP) values support this
methodology (13-15). However, published reports regarding
the value of the ACR in predicting UTP and assessing the
prognosis and progression of IgAN are rare. Therefore,
the purpose of the present study was to evaluate whether
the ACR is a reliable indicator of UTP in IgAN. In addition,
we compared the reliability of the ACR and UTP in
predicting complications of CKD and renal progression in
IgAN.
’ MATERIALS AND METHODS
A total of 201 inpatients with biopsy-proven IgAN were
enrolled in this study from January to December 2014. The
exclusion criteria were as follows: secondary causes of
mesangial IgA deposition (n=16) and urinary tract infection
(n=3). Of all patients evaluated, 182 satisfied the inclusion
criteria of the study. Of these 182, 104 were newly diagnosed.
All biopsy slides were evaluated by two pathologists using
the Oxford classification criteria (16). Among these
104 patients, 44 had regular follow-up for more than 6
months and were included in the renal progression analysis.
The patients’ demographic and clinical data, such as age,
gender and blood pressure, were collected during hospitaliza-
tion. Therapeutic use of an angiotensin-converting enzyme
inhibitor (ACEI) or angiotensin receptor blocker (ARB),
prednisolone and/or other immunosuppressive agents were
recorded. The main baseline characteristics of all 182 patients
are shown in Table 1. The patients underwent regular visits
at 3-month intervals. As with CKD, a minimal percentage
change in the estimated GFR (eGFR) (25% or greater) was
defined as progression (12). The follow-up time corresponded
to the interval between renal biopsy and a decline in the eGFR
of 25% or more compared with baseline or the last outpatient
visit and patients were classified as having progression when
their eGFR values decreased by 25% or more.
A first-morning void sample was collected from every
patient for albumin and creatinine assessment. Each patient
was then instructed to collect an accurate 24-hour urine
sample for total protein quantification on the next day. Both
ACR and UTP values were determined as the means of three
measurements during hospitalization. To assess CKD com-
plications, blood samples were taken on the same day as the
24-hour urine collection, 6 months later and at the last
follow-up. Urine albumin and creatinine concentrations were
measured via nephelometry and chromatometry, respec-
tively, in the clinical laboratory department of our hospital.
The ACR (mg/g) was calculated as the spot urine albumin
concentration divided by the corresponding spot urine
creatinine concentration. UTP (g/24 h) was measured using
a turbidimetric method. In addition, common complications
of CKD, indicated by the levels of serum albumin, hemoglo-
bin, bicarbonate, potassium, phosphorus, total cholesterol and
triglycerides, were measured. Other indexes, such as serum
uric acid and cystatin C, were also measured. Adult eGFR
values were calculated using the CKD-EPI equation (17),
whereas the eGFR values for minors were calculated using the
Filler formula (18).
This study was approved by The First Affiliated Hospital of
Guangzhou University of Traditional Chinese Medicine Ethics
Committees and written consent was obtained from each
patient. Parents provided informed consent for minor children.
Table 1 - Characteristics of the study population, stratified by eGFR level.
Characteristic Total Stages of CKD p-value
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
No. of participants 182 74 44 32 16 16 —
Age (y) 33.3±12.9 26.1±10.6 38.5±10.8 39.6±13.2 31.6±9.5 41.1±13.8 0.0001
Female 57.1 51.4 68.2 56.3 62.5 50.0 0.4430
Serum creatinine (mmol/L) 166.2±203 70.9±14.3 88.0±15.3 155.6±32.8 285.5±37 723.6±286.7 0.0001
Uric acid (mmol/L) 427.2±123.4 366.1±96.6 386.6±73.1 530.9±112.5 547.9±83.3 516.8±145 0.0001
eGFR (ml/min/1.73 m2) 76.7±41.9 116.5±20.5 80.2±7.5 42.4±8.5 20.7±4.0 7.5±3.1 0.0001
Cystatin C (mg/L) 1.6±1.1 0.9±0.2 1.1±0.3 1.9±0.7 3±0.3 4.3±0.6 0.0001
ACR (mg/g) 665.3
[511.1-837.3]
295.9
[214.7-409.4]
792.0
[510.6-967.1]
715.6
[515.9-966.5]
2044.0
[921.2-3386.0]
2910.4
[2405.2-4644.0]
0.0001
UTP (g/24 h) 0.9 [0.7-1.1] 0.4 [0.3-0.6] 0.8 [0.6-1.3] 0.9 [0.7-1.4] 2.4 [1.3-5.2] 2.7 [1.7-3.1] 0.0001
MAP (mmHg) 95.5±16.7 85.7±8.9 95±14.8 98.2±8.4 116.2±26 115.7±13.1 0.0001
Bicarbonate (mmol/L) 24.4±3.4 25.3±2.3 25.9±2.8 24.3±2.5 21.6±5.2 19.7±2.9 0.0001
Phosphorus (mmol/L) 1.4±0.3 1.3±0.2 1.2±0.2 1.4±0.2 1.5±0.2 2.1±0.3 0.0001
Potassium (mmol/L) 4.2±0.5 4±0.4 4.1±0.4 4.3±0.4 4.6±0.6 4.7±0.5 0.0001
Hemoglobin (g/L) 120.3±24.2 130.1±17.6 126.3±22.8 116±18.2 105.5±23 81.8±20.1 0.0001
Albumin (g/L) 37.8±7.2 38.8±8.5 38.6±7.0 38.0±4.6 34.2±4.6 34.8±5.9 0.0001
Triglycerides (mmol/L) 1.7±1.2 1.3±0.8 1.7±1.1 2.5±1.8 2.2±1.0 1.7±1.0 0.0001
Cholesterol (mmol/L)
Oxford classification
5.2±1.9 5.4±2.4 5.1±1.7 5.4±1.7 5.6±1.1 4.6±1.1 0.1556
M(0/1) 116/66 54/20 26/18 17/15 12/4 7/9 0.0800
S(0/1) 108/74 52/22 32/12 13/19 6/10 5/11 0.0010
E(0/1) 167/15 74/0 41/3 28/4 14/2 10/6 0.0000
T(0/1/2) 142/34/6 74/0/0 37/7/0 22/10/0 8/8/0 1/9/6 0.0000
Therapy 64.8 54.1 63.6 87.5 62.5 75.0 0.0190
Values are percentages, numbers, means ± SDs or medians [95% CI]. Therapy includes immunosuppressive agents and ACEI or ARB use.
MAP = mean arterial pressure; M = mesangial hypercellularity; S = segmental glomerulosclerosis; E = endocapillary hypercellularity; T = tubular atrophy
and interstitial fibrosis.
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Statistical analysis
Population characteristics are reported across the categories
of CKD based on eGFR levels. Continuous data are expressed
as the means ± standard deviations (SDs) or as medians, as
appropriate and categorical data are expressed as numbers
(percentages). The distributions of each characteristic, with the
exception of age, hemoglobin, uric acid and the eGFR, were
explored and found to be skewed. The Kruskal-Wallis H test
was used to compare five subgroups of each baseline data set
with regard to all parameters other than sex and parameters
of the Oxford classification, which were compared using the
Chi-square test and/or Fisher’s exact Chi-square test. Addi-
tionally, Spearman’s rank correlation was used to compare
ACR and UTP values, as both of these demonstrated skewed
distributions. The ability of the ACR, at various cutoffs, to
predict UTP ‘thresholds’ of X0.15, 0.3 and 1.0 g/24 h was
determined from receiver operating characteristic (ROC) curve
analysis and by calculating associated sensitivities, specificities
and the area under the ROC curve (AUC). An ROC curve is a
graphic plot of the sensitivity versus (1 -specificity) for a binary
classifier system. Restricted cubic splines were used to model
the association between ACR and UTP values and common
complications of CKD. As the placements of knots are not as
important as the numbers of knots selected for restricted cubic
splines (Jonas VB, Barclays UK & E RBB, 2012, unpublished
data), 4 knots were determined after attempting all 3
regression runs (k=3, 4 and 5) and knot values were based
on Harrell’s recommended percentiles. Knots were specifically
placed at 19.95, 405.067, 1132.69 and 4619.71 mg/g for the
ACR and 0.105, 0.5334, 1.4289 and 6.07 g/24 h for UTP. A
canonical correlation analysis (CCA) was conducted to identify
correlations between baseline proteinuria and the Oxford
classification. The prognostic values of the ACR and UTP for
renal progression were explored using univariate analyses
and a Cox proportional hazard regression model. Variables
including the ACR, UTP, age, sex, blood pressure and the CKD
stage were entered into the Cox regression model. Hazard
ratios (HRs) or odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated and significance was set at po0.05
(two-sided). All analyses were conducted using Stata, version
12.0 (StataCorp LP).
’ RESULTS
The baseline characteristics of all 182 participants are
presented in Table 1. Among our study participants, the
mean age was 33.3±12.9 years and 57.1% were female. The
mean eGFR was 76.7±41.9 ml/min per 1.73 m2. The median
spot ACRwas 665.3 mg/g and the median UTP was 0.9 g/24 h.
As the eGFR decreased, the ACR, but not UTP, increased.
Significant differences were identified between five sub-
groups based on use of an ACEI or ARB, prednisolone and/
or other immunosuppressive agents (p=0.0190). With respect
to the Oxford classification, significant differences were
identified among the five subgroups based on S, E and
T scores. The backgrounds of 44 patients in the prospective
cohort are shown in Table 2.
A strong correlation was found between ACR and UTP
measurements (r=0.7992, p=0.0000). When our analysis was
stratified by subgroups based on eGFR levels, all subgroups
showed a good correlation, except in CKD stage 5 (Figure 1).
Using the ROC curves, ACR discriminant values of 125.15,
154.44 and 760.31 mg/g reliably predicted UTP values ofX0.15,
0.3 and 1.0 g/24 h, respectively (Figure 2). The corresponding
AUC values were 0.84, 0.84 and 0.90.
In a continuous analysis, both higher ACR and higher UTP
values were associated with higher cholesterol levels (Figure 3F)
and lower albumin levels (Figure 3B). Neither ACR nor UTP
measurements demonstrated positive or negative correlations
with uric acid levels (data not shown). Higher ACR values were
associated with lower hemoglobin (Figure 3A) and bicarbonate
(Figure 3G) levels and higher phosphorus (Figure 3D), potas-
sium (Figure 3C) and cystatin C (Figure 3H) levels. However,
higher levels of UTP were associated with higher hemoglobin
(Figure 3A) and triglyceride (Figure 3E) levels.
Table 2 - Characteristics of patients in the prospective cohort, stratified by eGFR level
Characteristic Total Stages of CKD p-value
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
No. of participants 44 19 15 8 2 0 —
Age (y) 31.9±11.8 26.5±10.4 38.5±10.6 35.3±10.6 21±11.3 — 0.0111
Female 63.6 52.6 73.3 75.0 50.0 — 0.5300
Serum creatinine (mmol/L) 99.3±53.2 71.1±16.2 84.8±12.7 147.3±35.1 283.5±37.5 — 0.0001
Uric acid (mmol/L) 420±121.2 357.8±99.7 406.6±79.6 572.3±91.1 502±176.8 — 0.0011
eGFR (ml/min/1.73 m2) 86.9±33.2 115.2±21.3 82.1±5.1 44.7±10.2 22.9±0.9 — 0.0001
Cystatin C (mg/L) 1.2±0.6 0.8±0.2 1.1±0.3 1.7±0.6 2.9±0.6 — 0.0001
ACR (mg/g) 512.5 [329.4-836.3] 218.1 [59.0-564.1] 760.3 [329.4-1181.4] 715.6 [346.0-2384.0] 2457.2 [1135.8-3778.6] — 0.0260
UTP (g/24 h) 0.8[0.6-1.3] 0.5[0.2-1.2] 1.1[0.7-1.6] 0.7[0.3-3.6] 4.2[1.4-7.0] — 0.1731
MAP (mmHg) 92.0±16.3 84.7±10.0 93.9±13.5 100.0±9.4 115.7±60.8 — 0.0205
Bicarbonate (mmol/L) 25.3±2.3 25.4±2.0 25.9±3.1 23.8±1.0 25.1±0.1 — 0.1419
Phosphorus (mmol/L) 1.3±0.2 1.3±0.2 1.2±0.2 1.4±0.2 1.8±0.0 — 0.0522
Potassium (mmol/L) 4.1±0.4 3.9±0.4 4.0±0.4 4.5±0.3 4.5±0.6 — 0.0077
Hemoglobin (g/L) 122.2±18.6 126.3±18.2 122.5±16.9 118±20.2 97.5±19.1 — 0.2137
Albumin (g/L) 37.9±7.0 39.4±7.3 36.8±7.6 38.1±4.2 30.7±4.5 — 0.1090
Triglycerides (mmol/L) 1.7±1.2 1.2±0.5 2.0±1.2 2.1±1.8 3.0±1.4 — 0.0105
Cholesterol (mmol/L) 5.2±1.9 4.8±1.5 5.1±1.8 5.5±1.5 6.2±1.3 — 0.3044
Oxford classification 35/9 17/2 11/4 5/3 2/0 — 0.3270
M(0/1) 32/12 15/4 11/4 4/4 2/0 — 0.3610
S(0/1) 42/2 19/0 14/1 8/0 1/1 — 0.0120
E(0/1) 40/4/0 19/0/0 13/2/0 7/1/0 1/1/0 — 0.0940
Therapy 54.5 42.1 46.7 87.5 100.0 — 0.0810
245
CLINICS 2016;71(5):243-250 Albumin-to-creatinine ratio in IgAN
Huan L et al.
To assess associations between proteinuria and the Oxford
classification at the time of biopsy, a CCA model was
constructed for 104 patients. This model incorporated the
ACR, UTP and pathological parameters of the Oxford
classification. M1, E1, S1 and T1/T2 were present in
34.62%, 3.85%, 34.62% and 15.38% of the 104 patients,
respectively. CCA outputs are shown in Table 3. The
canonical correlation coefficient was equal to +0.4538
(p=0.0016). For the proteinuria set, the ACR correlation
coefficient (+0.7440) was higher than the UTP correlation
coefficient (+0.3224). For the Oxford classification set, the
highest canonical loading was observed for T scores
(+1.1388). Thus, higher tubular atrophy and interstitial
fibrosis scores were associated with greater ACR values.
The impact of the ACR and UTP on renal progression
was analyzed for 44 patients. Over a median follow-up of
12 months, clinical progression was observed in 6 patients.
Univariate analyses identified both the ACR (OR 8.57, 95%
CI 0.80-421.80, p=0.0326) and UTP (OR 9.62, 95% CI 0.89-
472.40, p=0.0229) as risk factors for eGFR decline. In the
multivariate Cox regression model, neither the ACR nor UTP
was a significant variable. The initial eGFR (p=0.044) was the
only significant parameter (Table 4).
’ DISCUSSION
Quantification of proteinuria is significantly important
with regard to monitoring disease activity, responses to
therapy and prognoses in patients with IgAN. Until recently,
physicians used UTP as the gold standard for diagnosing
and evaluating significant proteinuria levels. However, given
that 24-hour urine collection is time consuming and often
imprecise (10), other urinary protein excretion measurements
are needed to complement or replace this approach. Both
the KDOQI (11) and KDIGO (12) have recommended use
of the protein- or albumin-to-creatinine ratio in untimed
urine samples, rather than 24-hour urine collection, as the
preferred method for measuring proteinuria. Certain prior
studies have demonstrated a good correlation with regard to
the relationship between the urine protein-to-creatinine ratio
(PCR) and the UTP value in diabetic or non-diabetic patients
diagnosed with renal disease. However, few studies have
investigated this relationship and whether these ratios can
predict the progression of CKD even more reliably than UTP
measurements can in the particular case of IgAN.
In the present study, we found a strong correlation
between ACR and UTP values throughout the overall study
population. Except in the CKD stage 5 group, good corre-
lations were also observed when we divided the patients into
five subgroups based on eGFR levels. A previous study
showed that renal function has little influence on the urine
PCR (19). Moreover, proteinuria declines with glomerulo-
sclerosis and advanced stages of CKD exhibit disturbed
circadian blood pressure rhythms (20), structurally deficient
arterioles (21) and eGFR variability (22). Whether the
exception described above is due to the reasons discussed
here remains unknown. However, these findings are in
agreement with a published report (23).
In clinical settings, the UTP ‘threshold’ is defined to
evaluate the degree of kidney injury. Usually, a UTP value
less than 0.3 g/24 h is a criterion for complete remission
in IgAN patients. However, higher levels of proteinuria
(43.5 g/24 h) indicate severity in the nephrotic range and
are associated with faster progression of kidney disease and
increased risks of cardiovascular disease (24). In the present
study, the discriminant values required for spot urine ACR
values to predict UTP values at these ‘threshold’ levels were
calculated with excellent sensitivity, specificity and AUC
values. In general, a first-morning urine ACR X125.15,
154.44 or 760.31 mg/g should reliably predict UTP values
X0.15, 0.3 and 1.0 g/24 h, respectively. These results are
slightly different from the values cited in the KDIGO
guidelines (12). Furthermore, in clinical practice, UTP
o0.15 g/24 h and/or an ACR o30 mg/g are defined as
normal, but in our study, ACR values X125.15 mg/g were
equivalent to UTP values X0.15 g/24 h. The observation
that ACR values X760.31 mg/g were equal to UTP values
X1.0 g/24 h also differed from the result of a prior study
(23); this discrepancy may be due to the cause of CKD. These
discriminant spot ACR values are applicable to monitoring
clinical courses and responses to therapy. Based on previous
reports (11,12,14), a random urine aliquot is just as accurate
as a first-morning urine specimen in predicting proteinuria
and albuminuria. Experiments investigating whether our
findings can be extrapolated to random urine collections are
currently underway.
Figure 1 - The relationship between the albumin-to-creatinine ratio and 24-hour urine proteinuria by (a) chronic kidney disease stages
1-4 and (b) stage 5.
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Figure 2 - ROC curves for the albumin-to-creatinine ratio at various cutoffs to predict 24-hour urine proteinuria ‘thresholds’ ofX0.15 (A),
0.3 (B) and 1.0 (C) g/24 h.
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To our knowledge, few prior studies have evaluated the
performance of different proteinuria measurements in pre-
dicting renal events. A study of 98 non-diabetic outpatients
with chronic renal disease found that PCR and UTP values
similarly predicted ESRD when used in univariate analyses
but that the PCR was the only parameter for which
multivariate analyses demonstrated statistical significance
(24). However, proteinuria is not the same as albuminuria.
Another study of 700 diabetic patients found that compared
with albuminuria or proteinuria detected using 24-hour
urine specimens, the ACR was more strongly associated with
the risk of ESRD or doubling of creatinine levels (25). As the
pathological changes associated with different renal diseases
are distinct, whether these findings can be extrapolated to
non-diabetic patients is not clear. Here, in a cross-sectional
study, we showed that ACR values were significantly
associated with anemia, acidosis, hypoalbuminemia, hyper-
phosphatemia, hyperkalemia, hypercholesterolemia and
higher serum cystatin C. However, higher UTP values were
only associated with hypoalbuminemia and hypercholester-
olemia. Thus, ACR measurements displayed a stronger and
more stable association with CKD complications in IgAN.
Cystatin C is a 13-kDa basic protein of the cystatin super-
family of cysteine proteinase inhibitors that is a more sensitive
biomarker than serum creatinine in monitoring renal function
(26). In the current study, as the eGFR declined, serum cystatin
C increased. Moreover, according to the baseline character-
istics in this study, as the eGFR declined, the ACR, but not
UTP, increased. A previous study also observed a good
correlation between serum cystatin C and renal histology,
particularly with regard to interstitial cellular infiltration and
tubular atrophy in patients with IgAN (27). In agreement with
these results, our study also showed a better correlation
between the ACR and tubulointerstitial changes than between
UTP and these changes. As IgAN is not a disease with benign
progression, managing and preventing metabolic complica-
tions of CKD are vital to postponing ESRD.
In addition to our cross-sectional analysis, we performed a
prospective observational study to investigate the influence
of the ACR and UTP on long-term renal progression. By
univariate analysis, ACR and UTP values were identified as
the clinical risk factors that predicted X25% of eGFR
decreases. However, our multivariate analyses indicated that
neither the ACR nor UTP influenced renal progression. These
findings could be explained by the small follow-up sample
size, the use of treatment with immunosuppressive agents or
renin-angiotensin-aldosterone system inhibitors (28) and the
strong predictive effect of the baseline eGFR.
Our study also provides interesting data regarding the
correlation between proteinuria and pathological parameters of
the Oxford classification in renal biopsy. Many previous studies
have indicated that tubular atrophy and interstitial fibrosis, as
Figure 3 - Restricted spline curves for the unadjusted association between the albumin-to-creatinine ratio and 24-hour urine
proteinuria and levels of (A) serum hemoglobin, (B) serum albumin, (C) serum potassium, (D) serum phosphorus, (E) serum triglycerides,
(F) serum total cholesterol, (G) serum bicarbonate and (H) serum cystatin C.
Table 3 - Standardized coefficients for the proteinuria and Oxford classification variables.
Proteinuria variables Oxford classification variables
Characteristic ACR UTP M S E T
Standardized coefficient +0.7440 +0.3224 -0.2883 +0.0870 -0.5079 +1.1388
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indicated via initial renal biopsy, predict adverse renal outcomes
in patients with IgAN (29,30). Interestingly, we found that the
presence of T1/T2 was significantly associated with higher ACR,
but not UTP, measurements. Previous studies have shown that
proteinuria is a rigorous predictor of tubulointerstitial disease
progression and the decline of renal function (31,32). A
prospective study (33) enrolled 215 patients with CKD, among
whom 43 patients presented IgAN, to assess the relationships
between ACR levels, urinary monocyte chemoattractant protein-
1 (MCP-1) levels, macrophage numbers, in situ damage and
clinical outcomes. In subset analyses classified by histological
diagnosis, ACR measurements correlated with interstitial
macrophage numbers only in the cases of IgAN and focal
segmental glomerulosclerosis. Moreover, in the early and middle
stages of CKD, the proportions of total renal creatinine excretion
due to tubular secretion are fairly constant within a given
patient. However, total urine creatinine excretion actually
declines because extrarenal creatinine degradation increases with
declining renal function (26). For these reasons, the ratio of the
concentrations of urinary albumin and creatinine in a single
voided urine sample cancels out the time factor and correlates
well with GFR decline and tubulointerstitial changes.
The present study is unique in that it combined cross-
sectional and prospective follow-up data to evaluate the
utility of the ACR in monitoring renal progression. Previous
studies have shown that lead-time bias may limit estimations
and comparisons of kidney survival in IgAN patients when
only initial data are considered (34,35). In addition, the Oxford
classification was employed to explore associations between
pathological and clinical indexes in the current study. Finally,
all laboratory indexes were measured in a single clinical
laboratory department. In addition to the common complica-
tions observed with regard to CKD, uric acid and blood lipids
are frequently observed to rise in IgAN patients; thus, these
two parameters were included in our analyses.
This study is limited by its relatively small size and short
follow-up period. In addition, the study participants
demonstrating eGFR levels o15 ml/min per 1.73 m2 were
fewer than those in the other subgroups. Finally, because this
was an observational study, treatments differed based on
different physician preferences, such that we were unable to
examine therapeutic effects.
In conclusion, we have demonstrated a good correlation
between spot ACR and UTP values, except those pertaining to
CKD stage 5, in IgAN patients. Spot urine ACR values of
X125.15, 154.44 and 760.31 mg/g reliably predicted equivalent
UTP ‘threshold’ values of X0.15, 0.3 and 1.0 g/24 h,
respectively. ACR measurements were significantly associated
with anemia, acidosis, hypoalbuminemia, hyperphosphatemia,
hyperkalemia, hypercholesterolemia and higher cystatin C
levels. However, the association of UTP values with these
concurrent complications was not consistent. Baseline ACR
values demonstrated a stronger association with the Oxford
classification and correlated with renal progression. Analyses of
first-morning void samples and ACR measurements appear to
constitute a superior means of evaluating and managing CKD
complications compared with UTP measurements. Thus, spot
ACR measurements constitute a precise standard by which
proteinuria can be measured and are more reliable than 24-hour
urine protein specimens in predicting progression in IgAN.
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